News Headlines

  1. Andelyn Biosciences To Apply The AAV Curator® Platform To Manufacture Clinical Grade AAV For Drake Rayden Foundation For The Treatment Of Nonketotic Hyperglycinemia 2/17/2026

    Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected by Drake Rayden Foundation to apply the AAV Curator® Platform to manufacture clinical grade AAV for the Treatment of Nonketotic Hyperglycinemia (NKH), a rare, inherited metabolic genetic disorder caused by a mutation in the GLDC gene.

  2. BIOEMTECH And NorthStar Medical Radioisotopes Announce Strategic Supply Agreement For Actinium-225 To Support Preclinical Radiopharmaceutical Research 2/17/2026

    BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, today announced a strategic supply agreement with NorthStar Medical Radioisotopes (NorthStar) to secure a reliable supply and provide Actinium-225 (Ac-225) for use in preclinical studies conducted by BIOEMTECH customers.

  3. Eckert & Ziegler And UJF Significantly Increase Production Volume For Actinium-225 2/16/2026

    Berlin, Germany and Řež, Czech Republic, 16 February 2026. Eckert & Ziegler SE and the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, “UJF”) have successfully transitioned their joint Actinium-225 initiative into larger scale manufacturing using the facilities in Řež and Braunschweig.

  4. STADA And Bio-Thera Receive European Marketing Authorization For Gotenfia, A Biosimilar To Simponi 2/13/2026

    Global specialty, generic and consumer healthcare medicines company STADA and Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, have received a marketing authorization from the European Commission[1] for their Gotenfia® (golimumab) biosimilar referencing Simponi®.

  5. BioLife Solutions Signs Multi-Year Supply Agreement With Qkine Limited To Expand Its Product Portfolio Into The Rapidly Growing Cytokines Market 2/12/2026

    BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.

  6. JHS CEO Chris Preti Receives 2026 Person Of Influence Award 2/12/2026

    Spokane, WA. - The Spokane Journal of Business named Chris Preti, CEO of Jubilant HollisterStier (JHS), as one of its 2026 People of Influence.

  7. Subcutaneously Administered Nanotrastuzumab Matches Performance Of Herceptin HYLECTA In Minipig Study 2/12/2026

    Nanoform Finland Plc, the medicine performance-enhancing company, announced the results from a preclinical study designed to compare the tolerability and pharmacokinetics of Nanotratsuzumab, a nanoformed, novel, hyaluronidase-free, non-aqueous nanoparticle suspension of trastuzumab for subcutaneous delivery versus Herceptin HYLECTA™, a co-formulated product with Halozyme’s proprietary hyaluronidase enzyme marketed by Roche/Genentech.

  8. CARsgen Signs Strategic Cooperation Agreements To Expand CAR-T Commercial Manufacturing Base In Jinshan, Shanghai 2/12/2026

    CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that through its indirectly wholly-owned subsidiary CARsgen Diagnostics, it has signed Strategic Cooperation Agreements agreements with Shanghai Jingong Enterprise, which is a key platform enterprise in the Bay Area High-Tech Zone of Jinshan District, Shanghai.

  9. Altasciences Announces Chris Perkin Appointed To Board Of Directors; Marie-Hélène Raigneau Appointed Chief Executive Officer 2/12/2026

    Altasciences announced today that Chris Perkin has been appointed as a member of the company’s Board of Directors, effective Tuesday, February 24, 2026. Following a leadership transition that has been underway for the past 12 months, Marie-Hélène Raigneau, President of the company since April 2025, has been appointed Chief Executive Officer, also effective Tuesday, February 24, 2026.

  10. A New Chapter In ROIS Commercial Leadership 2/11/2026

    ROIS today announced the appointment of Kimberlee Steele as Chief Commercial Officer, effective from 1 March 2026.